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1. Introduction 
The Coleopteran Luciferin-Luciferase system is widely used in 
bioluminescence imaging (BLI) to track disease and other 
biological functions in-vitro and in-vivo.1 The most commonly 
used substrate in this assay is the naturally occurring D-luciferin 
(1, LH2 Ȝmax = 558 nm). In the presence of molecular oxygen, 
Mg2+ ions and ATP, LH2 is oxidised by luciferase to form 
oxyluciferin (2), an excited-state ketone species that releases a 
photon of light (558 nm) as it relaxes back to its ground-state 
(Scheme 1).2 
Scheme 1 
However, the light emitted by D-luciferin is strongly absorbed 
by melanin, blood and tissue and this makes imaging in small 
mammals particularly difficult. To allow better image resolution 
the light emitted should be of higher wavelength in the near Infra-
red (nIR) region (600 ± 750 nm). Fortunately, the luciferase 
enzyme has shown considerable tolerance to different substrates 
and several synthetic nIR luciferins have been made and tested.3-5 
A pioneer in this area, White prepared the amino-luciferin 
analogue 3 which had a red-VKLIWHGHPLVVLRQVSHFWUXPȜmax = 593 
nm) in-vitro compared to LH2,6 but was only about 10% as bright 
as D-luciferin. Cyclic amino modifications (4) by Miller and co-
workers resulted in emissions greater than 600 nm.7 Maki removed 
the benzothiazole core and replaced it E\H[WHQGHGʌ-conjugation 
(5), which led to substantial increases in emission wavelength (Ȝmax 
= 675 nm).8 This molecule as the HCl salt  has been shown to be 
particularly effective for sensitive bioluminescence deep tissue 
imaging9 and noninvasive imaging in moving animals.10 More 
recently extending conjugation of the benzothiazole by 
substituting for a suitable napthothiazole resulted in very red 
shifted analogues 6a,b (Ȝmax = 730 nm and 743) with mutant 
CBR2opt luciferases that proved particularly useful for highly 
resolved deep tissue imaging and tomography.11 Modifications to 
the thiazoline portion of LH2 have shown poorer results, with 
substitutions by lighter elements (7a and 7b) resulting in no or 
slight emission and heavier elements (7c) resulting in red-shifted 
weak emission (Fig. 1).12,13 Recently, compound 8 and the  HCl 
salt of 5 have shown brighter emission than LH2 at low substrate 
concentrations.9,14 Luciferase mutants have also been engineered 
to give brighter light for some analogues11,15 including compound 
4 under sub-saturating conditions.16 In 2014, we reported a S-
extended analogue of luciferin infraluciferin (9, iLH2) that 
exhibited nIR bioluminescence Ȝmax = 706 nm).17,18 Like other 
red-shifted synthetic luciferins, iLH2 (9) was less bright than LH2, 
but because of the higher proportion of light output above O = 600 
nm there is less attenuation and scatter of the signal by blood and 
tissue. This leads to better penetration because of a reduced signal 
to noise effect caused by light scattering.17 We are still interested 
in improving the light output of iLH2 and are investigating mutated 
luciferases and alternative iLH2 structures for wider applicability 
in a variety of challenging bioluminescence imaging applications.  
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Figure 1. Bioluminescence emissions of some synthetic red 
shifted luciferins 
The relatively lower light output of iLH2 (9) compared to LH2 
(1) could be due to a number of factors, such as catalytic turnover, 
product inhibition and radiationless decay caused by rotatable 
bonds. While we know that the Km values for iLH2 (9) and LH2 (1) 
with certain Fluc enzymes is comparable, the specific activity is 
100 times less and the L-enantiomer of iLH2 (9) causes some 
enzyme inhibition,17 the question of radiation-less decay has not 
been investigated. Comparing the two molecules iLH2 (9) has 
more degrees of freedom compared to LH2 (1) due to rotation 
about an extra single bond (Fig. 2). This could allow more changes 
of the excited state geometry LQWKHHQ]\PH¶VDFWLYH-site, causing 
greater radiation-less decay and a lower light output than LH2 (1). 
In this study, we have investigated whether synthesis of a more 
rigid infraluciferin framework with the same number of rotational 
single bonds as LH2 (1) affects bioluminescence light ouput. 
To rigidify the infraluciferin structure, it was thought that a 
carbon bridge could be constructed to connect either of the 
heterocycle rings to the alkene linker (Fig. 2). It is known that 
substitution of the heteroatoms in the thiazoline ring to C or N lead 
to inert compounds that give little or no light,12 Whereas 
modification of the benzothiazole heterocycle has been reported 
by Prescher for benzimidazole luciferin (10, BILH2) to give 
bioluminescence emission more red-shifted Ȝmax = 578 nm) than 
LH2 (1), but again with a lower quantum yield.19 Our hypothetical 
design structure 11 has incorporated this modification to allow a 
rigidifying linker in pyridobenzimidazole infraluciferin (12, 
PBIiLH2), where X = N so that aromaticity and conjugation (with 
the corresponding ketone from oxidation) can be maintained in the 
final compound. Whilst not completely rigid, this structure has the 
same degrees of freedom and rotatable single bonds as LH2 (1). 
Benzimidazole infraluciferin (13, BIiLH2) would serve as a 
comparison to PBIiLH2 (12) in the bioluminescence studies to test 
our hypothesis. 
 
Figure 2. Design hypothesis for rigid infraluciferins 
2. Results and discussion 
2.1. Docking of luciferin analogues in Ppy-Luc 
As these analogues scaffolds are different in size and shape than 
LH2 (1), we have used docking studies to predict the interaction 
between the adenylated luciferin structures and the luciferase 
enzyme. For this purpose, the crystal structure of the Photinus 
pyralis luciferase enzyme, bound to the adenylatHDQDORJXHƍ-O-
[N-dehydroluciferyl)-sulfamoyl]- adenosine (LH2-DLSA) (PDB 
accession number 4G36) was obtained.20 GOLD21 software 
version 5.4.1 was used for the docking studies. To test our system, 
we first performed the docking of the energy minimised structure 
of LH2-DLSA at the ATP-binding site. Energy minimisation was 
carried out using the MM2 calculation, Chem3D Pro software 
version 13.0.2.3021. Calculations were ran on a PC with a 2.3 
GHz-i5 processor and 8 GB RAM. The docking solutions were 
viewed using Discovery Studio Visualizer22 with the protein 
surface coloured by hydrophobicity. The docking result for the 
crystallised ligand was overlayed with the co-crystal structure and 
the calculated exhaustive root mean squared deviation (RMSD) 
was 0.7453, indicating a good prediction ability of our docking 
protocol. We decided to carry out a rigid molecular docking due to 
close similarity in the binding site between different 
crystallographic structures. 
Starting with the energy minimised structures of PBIiLH2-
DLSA and BIiLH2-DLSA, the GOLD wizard was used to carry out 
the molecular modelling. The binding site was defined to within 6 
c of the LH2-DLSA analogue and the docking was carried out 
using the slow method to identify six different solutions. By 
comparing the docking solutions to the binding mode of LH2-
DLSA, the pose of PBIiLH2-DLSA and BIiLH2-DLSA which gave 
the best overlay was selected for the basis of our docking model. 
Both PBIiLH2 (12 Fig. 3A) and BIiLH2 (13 Fig. 3B) fitted into 
the narrow and deep substrate binding site. Several proposed 
favourable hydrophobic interactions and hydrogen bonds are 
shown in Fig. 3C and 3D. This preliminary study showed that it is 
structurally possible to locate the analogues in the luciferin binding 
site and gave us added confidence that the real molecules may 
bioluminesce. 
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2.2. Synthesis of luciferin analogues 
To circumvent possible epimerisation of the carboxylic acid 
forms of the infraluciferin analogues and accurate quantification 
of enantiopurity, all substrates were prepared as racemic mixtures 
using DL-cysteine. We have previously shown that DL-iLH2 (9) 
is a competent substrate for bioluminescence and that the L-
enantiomer does not prohibit light production.18 The synthesis of 
BILH2 has been previously reported.19, 23 The Prescher synthesis19 
was repeated, but in our hands the demethylation of the phenol 
ether was capricious and gave us poor yields of intermediate 17. 
The route was modified by introducing a TBDMS protecting group 
on the phenol 14 with TBDMS-Cl to give 15 in 95% yield. The 
rest of the synthesis followed the Prescher route.19 The nitro group 
in 15 was reduced by catalytic hydrogenation to give the crude 
unstable diamine product, which was immediately reacted with 
$SSHO¶VVDOWLQGU\S\ULGLQHWRJLYHthe desired benzimidazole 16 
in a 50% yield over 2 steps. The TBDMS protecting group was 
readily cleaved with TBAF at room temperature to obtain the key 
benzimidazole nitrile 17 in excellent yield (90%). This was then 
condensed with DL-cysteine hydrochloride to give racemic BILH2 
(10) in 52% yield (Scheme 2) to compare against the racemic 
infraluciferin analogues.24 
  
Scheme 2. $SSHO¶VVDOW -dichloro-1,2,3-dithiazol-1-ium 
chloride. 
 The conformationally restricted, PBIiLH2 12 was synthesised 
in two steps. As 2-aminopyridine is known to condense with 1,4-
benzoquinone (18) in acidic conditions,25 the pyridobenzimidazole 
core was synthesised in an analogous fashion by a one-pot 
condensation/oxidation reaction between 1,4-benzoquinone (18) 
and 2-amino-4-cyanopyridine (19), to give the nitrile 20 in 72% 
yield. DL-cysteine was then condensed with nitrile 20 under 
refluxing conditions,26 after no product was obtained at room 
temperature, to give PBIiLH2 12 in 38% yield (Scheme 3). 
 
Scheme 3. 
For the synthesis of BIiLH2 (13) we followed a very similar 
route to our published infraluciferin (9) synthesis.18 This required 
the key aldehydes 24a,b, which we envisaged could be made from 
the oxidation of the corresponding methyl precursor 22. The 
synthesis of benzimidazole 22 was achieved by following a 
literature route to an analogous compound27 with the addition here 
of a protected hydroxyl group that could be unmasked in the final 
stages of the synthesis. Phenol 14 was protected with the 
triisopropylsilyl protecting group under standard conditions
 
(Scheme 4).28 Several other protecting groups were also trialled 
(Boc, MEM, Tosyl) but these were incompatible with the various 
stages of the final synthetic route. The triisopropylsilyl-protected 
benzimidazole 22 was synthesised by a one-pot reduction and 
cyclisation27 of 21 with H2, Pd/C catalyst in the presence of 
triehtylorthoformate to give a single benzimidazole product by 
A 
B 
C 
D 
Fig. 3. -   A and B - Pose prediction for PBIiLH2  and BIiLH2  in PpyLuc pocket; C and D - PBIiLH2 and BIiLH2 with predicted 
interactions; Colour code: Pink ± Hydrophobic interactions; Green ± hydrogen bonds 
Tetrahedron 4 
NMR in 96% yield. The exact tautomeric form of the 
benzimidazole was not determined and we have drawn 22 as a 
representative structure. Oxidation of the aromatic methyl group 
to an aldehyde was attempted on 22 using selenium dioxide and 
TBHP,29 but this did not work and gave unidentified products. 
Therefore 22 was protected using the SEM group as there is 
literature precedent of it being cleaved from sensitive biological 
substrates.30 We observed that the SEM group protected each 
tautomer of the benzimidazole (23a:23b, 1:1) and these were 
separated in 41% and 40% isolated yields respectively. Both 
isomers were separated by column chromatography and each was 
carried forward in the synthetic route. Oxidation of 23a,b was 
successful and key aldehydes 24a (70%) and 24b (96%) were 
obtained in good yields. Each aldehyde was reacted with key 
phosphonate 25 in a Horner-Wadsowrth-Emmons (HWE) reaction 
from our previously published route for infraluciferin (9).17 Our 
reported Masamune and Rouche conditions (DBU and LiCl) 18,31 
gave no product, in this case. A variety of bases were screened 
(NaH and K2CO3) and the use of KOtBu in the HWE reaction 
yielded the desired products 26a (70%) and 26b (35%) in modest 
yields. The triisopropylsilyl group was easily cleaved by TBAF at 
this stage, in good yields (27a 65%, 27b 93%), as attempts at 
removing it at after the thiazoline had been constructed were 
unsuccessful. The thiazoline, especially in the S-extended 
analogues we have prepared is more prone to oxidation than 
luciferin. As a precaution all synthetic manipulations, workups and 
purifications when the thiazoline was formed were performed in 
degassed solvents. Cyclisation to the thiazoline (28a 65%, 28b 
67%) was achieved by treating thioamides 27a,b with DAST at -
78 qC. Finally, the SEM group was cleaved with Tin (IV) 
chloride30 to give the methyl ester 29 in 95% yield. The ester was 
found to be unstable in base (LiOH) and so was hydrolysed with 
porcine liver esterase17 to give BIiLH2 (13). The ester and final 
compound BIiLH2 (13) were again isolated as single 
benzimidazole tautomers by NMR, but the exact structures were 
not determined. 
  
  
Scheme 4. SEMCl = 2-(trimethylsilyl)ethoxymethyl chloride; 
TBHP = tert-butyl hydroperoxide; diethylaminosulfur 
trifluoride; PLE = porcine liver esterase 
2.3. Bioluminescence activity and spectra of analogues with 
wild-type and thermostable luciferases.  
Wild-type (WT) Photinus pyralis firefly luciferase (Fluc), 
thermostable variants and also click beetle red were purified by 
nickel NTA chromatography and their basic properties were 
examined with compounds D-LH2 (1), DL-BILH2 (10), DL-iLH2 
(9), DL-BIiLH2 (13) and DL-PBIiLH2 (12). Specific activities 
were first collected by integrating light over the first 2 min of 
emission using the PhotonIMAGER Optima (PIO) small animal 
imager. Natural D-LH2 (1) gave the highest activity with all 
enzymes, followed by DL-BILH2 (10), which gave about 100-
times lower activity with the majority of enzymes, except CBR, 
with which activity was 1000-times lower than with D-LH2 (1) 
(Fig. 4). With x2 and x11 Flucs DL-iLH2 (9) gave a similar level 
of activity as with the non-extended DL-BILH2 (10), demonstrating 
the efficacy of engineered Flucderivatives when used with iLH2 
(9), since they are more active and have less decay of signal (SI 
Fig). Enzymes gave the lowest activity with DL-BIiLH2 (13), 
which was ~10 000-times less bright than WT Fluc and the 
majority of the other enzymes with D-LH2 (1), but ~250 000 times 
less active with CBR. However, the rigidified version DL-PBIiLH2 
(12) showed an enhancement in luminescence activity with WT 
Fluc compared to DL-iLH2 (9) and also compared to DL-BIiLH2 
(13) with each enzyme: 3-fold with WT and x11 Flucs, 5-fold with 
x2 Fluc, 9-fold with x5 Fluc and 20-fold with CBR. The activity 
of CBR with DL-PBIiLH2 (12) was of a similar level as with both 
DL-iLH2 (9) and DL-BILH2 (10). Therfore we can rationally 
improve the activity of different luciferases with an electronically 
modified extended infraluciferin backbone by making it more rigid 
and reducing its degrees of freedom. 
The emission colours of enzymes with each of the analogues 
were assessed by acquiring spectra through successive 30nm pass-
band filters in the PhotonIMAGER Optima (PIO). With D-LH2 (1) 
enzymes displayed their expected different colours with WT, x5, 
x11, x2 and CBR giving Omax values ranging from 555nm (WT, 
x5, x11), 561nm (x2) and 614nm (CBR) (Table 1). As previously 
described the emission colours (Fig. 5) of enzymes with DL-iLH2 
(9) also showed a colour-shifting effect, producing Omax values 
red-shifted compared to with D-LH2 (1) by 104nm for CBR and 
124-142nm for the Flucs. Interestingly, a colour-shifting effect 
was also seen with DL-BILH2, (10) with both x2 Fluc displaying 
a 23nm red-shift compared to WT, x5 and x11 and CBR displaying 
a 53nm shift, which is similar to the colours emitted with D-LH2 
(1), albeit CBR displayed a smaller blue-shifted peak at ~560nm. 
 
 
 
Fig. 4. -  Specific activities of wild-type (WT) Photinus pyralis 
firefly luciferase and thermostable x2, x5 and x11 derivatives and 
click beetle red luciferase (CBR). Enzyme activities were measured 
immediately upon adding substrate for 2 min in the PhotonIMAGER 
Optima (PIO).  
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Table 1. Primary and secondary bioluminescence peak wavelengths 
of enzymes with different compounds (O/nm). Values acquired from 
smoothing (spline fitting) of spectra acquired in bandpasses in the 
PIO. 
 
D-LH2 
(1) 
DL-BILH2 
(13) 
DL-iLH2 
(9) 
DL-BIiLH2 
(10) 
DL-PBIiLH2 
(12) 
WT 555 567 697 561 614 
x2 561 590 691 572 596 
x5 555 561 679 555 596 
x1
1 
555 561 685 561 608, 714 
CB
R 
614 620, 555 720 620 620 
 
The situation was different for the extended electronically 
altered compound DL-BIiLH2 (13) since the emission peak 
wavelengths of enzymes were markedly blue-shifted compared to 
those with DL-iLH2 (9) and were more akin to those emitted with 
D-LH2 (1) or DL-BILH2 (10). This may be explained by twisting 
of the light emitting oxy form of BIiLH2 in the active site of the 
luciferase. However, a red-shift observed with CBR indicated that 
a specific colour-shifting mechanism was also active for this 
compound. Emission colours with DL-PBIiLH2 (12) were more 
red-shifted and remarkably, we detected a >100nm red-shifted 
secondary peak of emission x11 Fluc with DL-PBIiLH2 (12). 
Although this peak was relatively unstable to time and 
temperature, it indicated the possibility that due to the increased 
rigidity of the light emitting oxy form it has access to relatively 
redshifted colour forms compared to the light giving oxidized form 
(ketone cf Scheme 1) of iLH2 (9). If PBIiLO (30) is 
conformationally stabilized to be relatively planar around the only 
rotatable V-bond in the active site of x11 Fluc, this red shifted peak 
might be explained by the stabilization of resonance forms 
accessible because of greater conjugation (Fig. 6). Bimodal 
bioluminescence emission is not unusual and has been explained 
by stablisation of each of the resonance forms of the anionic ketone 
of the oxidized species.4,32 We speculate that x11 Fluc is able to 
stabilize the enolate form leading to red emission. Bioluminescene 
studies of x11 Fluc with DL-PBIiLH2 (12) as a function of pH (Fig. 
7) showed an increased bimodal emission with increasing pH. 
Recent reports suggest an acidic H-bonding network may stabilise 
the yellow-green emitting phenolate form of luciferins.32 In the 
x11 Fluc/DL-PBIiLH2 (12) system increasing the pH may remove 
this in favour of stabilization of the red emitting enolate form.    
Figure 5.  Bioluminescence spectra of WT, x2, x5 and x11 Flucs and CBR. Spectra acquired by integrating light for 1 min in different filters 
and fitted with a spline smoothing function in PRISM.  
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Figure 6. Potential resonance forms of light emitting PBIiLO (30) in 
its deprotonated form. 
 
 
3. Conclusion 
The synthesis of a rigid analogue PBIiLH2 (12) of iLH2 (9) has 
been achieved in two steps in an attempt to improve the brightness 
of S-extended analogues of LH2 (1). Its bioluminescence activity 
was compared with its non-rigid counterpart BIiLH2 (13) which in 
turn was compared to its non S-extended analogue BILH2 (10). 
The results show that both S-extended analogues PBIiLH2 (12) and 
BIiLH2 (13) gave red shifted bioluminescence emissions with 
respect to LH2 (1) with wild type and thermostable luciferases 
ranging from 6-159 nm. Most strikingly the rigid analogue 
PBIiLH2 (12) gave a secondary emission of 714 nm with Fluc x11, 
comparable to the leading red shifted S-extended analogues 6a,b 
and iLH2 (9) reported.11,16,17 Although the rigid S-extended 
analogue PBIiLH2 (12) was not brighter than iLH2 (9) or its parent 
benzimidazole luciferin BILH2 (10), it did show enhanced 
brightness compared to its non-rigid analogue BIiLH2 (13) with 
each enzyme tested. The greatest increase in activity was 20-fold 
with CBR which also gave similar brightness for all three 
luciferins iLH2 (9), BILH2 (10) and PBIiLH2 (12). The concept of 
reducing the degrees in freedom in S-extended analogues of LH2 
(1) by synthetic rigidification has been demonstrated and we are 
investigating the refinement of this strategy on other analogues to 
investigate the brightness of red shifted luciferins. 
4. Experimental section 
4.1. General 
Experiments were carried out in flame dried glassware, in 
anhydrous solvents and under a positive flow of nitrogen or argon 
unless aqueous chemistry was involved. Temperatures of 0 °C 
were achieved using an ice-water bath. Cryogenic temperatures 
were obtained using a solid CO2 ± acetone bath (-78 °C). 
Commercially available solvents and reagents were used without 
further distillation. The petroleum ether used in purification 
procedures is the fraction that boils in the range of 40 ± 60 °C. A 
solvent purification system (SPS) was used to obtain anhydrous 
solvents where needed. Thin layer chromatography (TLC) was 
carried out on Merck aluminium backed DC 60 F254 0.2 mm pre-
coated plates. Visualisation of the plates was done under 
ultraviolet light and then stained with potassium permanganate 
solution where required. Flash column chromatography was 
performed on Gedran® silica gel 60, 40-ȝP 
All 1H and 13C NMR spectra reported were recorded on a 
Bruker Avance III 600 MHz spectrometer, unless stated otherwise. 
All 31P NMR spectra were recorded on a Bruker Avance III 400 
MHz spectrometer. 7KHFKHPLFDO VKLIW į IRU WKH UHVRQDQFHV LQ
spectra have been reported in parts per million (ppm) relative to 
the NMR solvent peaks, whilst coupling constants (J) are quoted 
in Hertz (Hz). 13C NMR spectra were recorded as proton 
decoupled spectra at 151 MHz, and DEPT, COSY, NOESY and 
HSQC spectra were obtained to aid in complete assignment. A 
3HUNLQ (OPHU 6SHFWUXP  )7,5 ZLWK 6SHFWUXP  ȝ$75
machine was used to record IR spectra. Mass spectra were 
obtained on a ThermoMAT900 and an Accela LC- Finnigan LTQ 
instruments. Melting points are uncorrected and were recorded on 
Electrothermal IA9300 machine. iLH2 and phosphonate 25 were 
synthesised as previously reported.18 
4.2. Synthesis of luciferin analogues BILH2 (10), PBIiLH2 (12) 
and BIiLH2 (13) 
4 .2 .1 .  4-( ter t -butyld imethyls i lyloxy) -2 -ni t r oa ni l ine 
(15 )  
To a solution of 4-amino-3-nitrophenol (14) (3.00 g, 19.6 
mmol) and imidazole (2.66 g, 39.2 mmol) in DMF (20 mL) was 
added TBDMS-Cl (4.00 g, 26.5 mmol) at room temperature and 
stirred for 24 h. The reaction was extracted with Et2O (3 x 20 mL), 
the organic layers combined, dried (MgSO4), and filtered. After the 
volatile materials were removed in vacuo, the crude product was 
used without further purification. The product 15 was obtained as 
a red solid (5.00 g, 95%); mp 100 ºC; (lit.34 98 ± 100 ºC); Rf = 0.80 
(80% EtOAc/hexane); 1H NMR (400 MHz, CDCl3į+G
J = 8.0, ArH), 6.97 (1H, d, J = 4.0, ArH), 6.71 (1H, dd, J = 8.0, 
4.0, ArH), 0.98 (9H, s, SiC(CH3)3), 0.19 (6H, s, OSi(CH3)2). The 
data was in agreement with the literature.33 
6-(tert-Butyldimethylsilyloxy)-1H-benzo[d]imidazole-2-
carbonitrile (16) 
To a solution of 4-(tert-butyldimethylsilyloxy)-2-nitroaniline 
(15) (1.75 g, 6.52 mmol) in MeOH (5 mL) was added 10% 
palladium on carbon (0.550 g) as a slurry in MeOH (5 mL) at room 
temperature. The solution was degassed with Ar, purged with H2 
3 times, and stirred for 7 h under a H2 atmosphere (balloon). The 
mixture was filtered through celite and the filtrate concentrated in 
vacuo to obtain the diamine product in crude form as a purple oil. 
Without further purification, this was dissolved in anhydrous 
S\ULGLQHP/DQG$SSHO¶VVDOWJPPRODGGHGDW
ÛC. The mixture was stirred at room temperature for 24 h. The 
mixture was concentrated under reduced pressure and the crude 
product was purified by flash column chromatography (20% 
EtOAc/hexane) to give 16 (1.66 g, 60%) as a pale yellow solid; mp 
178 ºC; Rf     (W2$FKH[DQH ,5 ȣmax (solution in 
CDCl3): 2953, 2930, 2892, 2239, 1626 cm-1; 1H NMR (400 MHz, 
CDCl3į+G- $UH), 7.05 (1H, s, ArH), 7.02 (1H, 
d, J = 8.0, ArH), 1.03 (9H, s, SiC(CH3)3), 0.25 (6H, s, OSi(CH3)2). 
13C NMR (150 MHz, CDCl3 į  &), 125.2 (CH), 121.3 
(CH),112.7 (CH), 25.1 (CH3), 19.0 (C), 4.4 (CH3); HRMS (ESI+) 
Calcd. for C14H20N3OSi [M + H] + 274.1376, found 274.1375. 
2-Cyano-6-hydroxybenzimidazole (17) 
To a solution of silyl ether 16 (0.200 g, 0.732 mmol) in THF 
(10 mL) was added 1M tetrabutylammonium fluoride (0.16 mL, 
1.4 mmol) at 0 ÛC. The reaction was stirred for 2 h at room 
temperature. The reaction mixture was then concentrated under 
reduced pressure and the crude product purified by flash column 
chromatography (80% EtOAc/hexane) to give 17 (0.130 g, 90%) 
Fig. 7. Bioluminescence emission of  x11 Fluc with DL-PBIiLH2 
(12) as a function of pH. Spectra acquired by integrating light for 1 
min in different filters.  
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as a yellow solid; mp 178 oC; Rf = 0.25 (80% EtOAc/hexane); 1H 
NMR (400 MHz, Methanol-d4) į 7.51 (1H, d, J  = 8.0, ArH), 6.96 
(1H, dd, J = 8.0, 4.0, ArH), 6.92 (1H, d, J = 4.0 Hz, ArH). The data 
is in agreement with the literature.15 
2-(6-hydroxy-1H-benzo[d]imidazol-2-yl)-4,5-dihydrothiazole-
4-carboxylic acid (10) 
To a solution of nitrile 17 (60.0 mg, 0.377 mmol) in MeOH (2 
mL) and H2O (1 mL) was added DL-cysteine hydrochloride 
monohydrate (70.1 mg, 0.399 mmol), K2CO3 (54.0 mg, 0.391 
mmol) at room temperature and the suspension was stirred for 30 
min. The mixture was acidified with 3 M HCl to pH = 3. The 
MeOH was removed in vacuo, and the remaining solution was 
extracted with EtOAc (3 x 100 ml). The organic layers were 
combined, dried (MgSO4), filtered and concentrated under reduced 
pressure to obtain the crude product that was purified by flash 
column chromatography (100% EtOAc - 1% AcOH/EtOAc). The 
product 10 was obtained as a yellow solid (98 mg, 93%) (lit. [15] 
82%). m.p. 203 ºC; 1H NMR (400 MHz, Methanol-d4) į 7.48 (1H, 
d, J = 8.9, ArH), 6.94 (1H, d, J = 2.3, ArH), 6.85 (1H, dd, J = 8.9, 
2.3, ArH), 5.27 (1H, app t, J = 9.0, C=NCH(COOH)CH2), 3.71 
(2H, d, J = 9.0, CH2S). The data is in agreement with the 
literature.15 
4 .2 .2 .  8-hydr oxybenzo[ 4 ,5] imida zo[ 1 ,2 -a ] pyr id ine-
3-ca r boni t r i l e  (20 )  
To a solution of 1,4-benzoquinone 18 (540 mg, 5.00 mmol) in 
AcOH (1.25 mL) was added a solution of 2-amino-4-
cyanopyridine (290 mg, 2.50 mmol) in AcOH (0.75 mL). The 
mixture was diluted with H2O (0.75 mL) and boiled for 5 mins 
until the mixture turned red. The mixture was cooled quickly to 
room temperature in an ice bath and then acidified with 6M HCl 
(1.25 mL) and diluted with H2O (15 mL). The aqueous layer was 
extracted with Et2O (3 x 15 mL), cooled to 0 qC and basified to pH 
8 with solid Na2CO3. The crude, brown precipitate formed was 
filtered, dried under vacuum, and purified by flash column 
chromatography (10% MeOH/EtOAc) to give 20 as a yellow solid 
(379 mg, 1.81 mmol, 72%); mp 171-173 ºC; Rf 0.62 (10% 
0H2+(W2$F,5ȣmax (solid) 3500 (br), 3086, 2229, 1641 cm-1; 
1H NMR (600 MHz, Methanol-d4) į8.77 (1 H, dd, J =7.1, ArCH), 
8.05 (1 H, s, ArCH), 7.68 (1 H, d, J =8.9, ArCH), 7.43 (1 H, d, J 
=2.3, ArCH), 7.14 (1 H, dd, J =8.9, 2.3, ArCH), 7.02 (1 H, dd, J 
=7.1, ArCH); 13C NMR (151 MHz, Methanol-d4 į  C), 
146.5 (C), 139.8 (C), 131.1 (C), 128.7 (CH), 124.9 (CH), 121.5 
(C), 119.6 (CH), 118.6 (CH), 112.9 (C), 111.3 (CH), 97.2 (CH); 
m/z (ES-) 208 (60%, [M-H]-); HRMS for C12H6N3O [M-H]- calcd. 
208.0511, found 208.0501. 
2-(8-hydroxybenzo[4,5]imidazo[1,2-a]pyridin-3-yl)-4,5-
dihydrothiazole-4-carboxylic acid (12) 
To a suspension of nitrile 20 (177 mg, 0.85 mmol) in EtOH (5 
mL) were added D, L-cysteine (205 mg, 1.69 mmol) and NaHCO3 
(286 mg, 3.40 mmol) and the mixture heated at reflux for 48 h. 
The solvent was removed in vacuo and the remaining residue 
washed with ice-cold Et2O (3 x 10 mL). The residue was then 
dissolved in ice cold H2O (4.2 mL) and acidified with 2M HCl to 
pH 2. A precipitate was formed that was filtered and dried to give 
12 as a tan solid (100 mg, 0.32 mmol, 38%); mp 279 q&,5ȣmax 
(solid state) 3253 (br), 3063, 2927, 1719; 1H NMR (600 MHz, 
DMSO-d6) į 13.11 (1 H, s, CO2H), 9.80 (1 H, br s, OH), 8.97 (1 
H, d, J =7.1, ArCH), 7.84 (1 H, s, ArCH), 7.71 (1 H, d, J =8.7, 
ArCH), 7.59 (1 H, s, ArCH), 7.32 (1 H, d, J =7.1, ArCH), 7.10 (1 
H, dd, J =8.8, 2.0, ArCH), 5.39 (1 H, t, J =8.9, CHCO2H), 3.82 ± 
3.77 (1 H, m, CH2S), 3.72 ± 3.68 (1 H, m, CH2S); 13C NMR (151 
MHz, DMSO-d6) 171.6 (C), 167.1 (C), 153.7 (C), 145.0 (C), 138.2 
(C), 131.8 (C), 129.4 (C), 126.8 (CH), 120.0 (CH), 118.0 (CH), 
117.1 (CH), 107.8 (CH), 96.5 (CH), 78.5 (CH), 35.4 (CH2S); m/z 
(ES+) 314 (100%, [M+H]+); HRMS for C15H12N3O3S [M+H]+ 
calcd. 314.0599, found 314.0587. 
4 .2 .3 .  2-ni t r o -4 -( ( t r i isopr opyls i lyl )oxy)a n i l ine ( 21)  
To a solution of 4-amino-3-nitrophenol (1.00 g, 6.48 mmol) in 
CH2Cl2 (30 mL) was added imidazole (0.70 g, 10.3 mmol). The 
mixture was cooled to 0 °C, triisopropylsilyl chloride (1.78 mL, 
8.32 mmol) added, the mixture allowed to warm to room 
temperature and stirred for 16 h. The resultant mixture was diluted 
with CH2Cl2 (30 mL), washed sequentially with a saturated 
solution of NaHCO3 (20 mL), water (20 mL) and brine (20 mL), 
and then the organic layer dried (MgSO4), filtered and 
concentrated under reduced pressure to give the crude compound 
as a bright red gelatinous solid which was purified by passing 
through a silica plug (50% EtOAc/hexane) to give 21 as a bright 
red crystalline solid (2.00 g, 6.48 mmol, 99%); mp 92-94 °C; Rf 
(W2$FKH[DQH,5ȣmax (solid state) 3500, 3346, 2939, 
2861, 1561 cm-1; 1H NMR (600 MHz, CDCl3į+GJ = 
2.9, ArCH), 7.03 (1 H, dd, J = 8.9, 2.9, ArCH), 6.71 (1 H, d, J =  
8.9, ArCH), 5.81 (2 H, br s, NH2), 1.27 ± 1.23 (3 H, m, CH(CH3)), 
1.10 (18 H, d, CH(CH3) J =  7.4); 13C NMR (151 MHz, CDCl3į
146.8 (C), 139.7 (C), 131.9 (C), 130.1 (CH), 119.7 (CH), 114.5 
(CH), 18.0 (CH3), 12.6 (CH); m/z (ES+) 311 (100%, [M+H]+); 
HRMS C15H27N2O3Si [M+H]+ calcd. 311.1791, found 311.1792. 
2-methyl-6-((triisopropylsilyl)oxy)-1H-benzo[d]imidazole (22)  
To a stirred solution of 21 (2.00 g, 6.45 mmol) in MeOH (25 
mL) were added AcOH (7 drops), triethyl orthoacetate (2.36 mL, 
12.9 mmol), and 10% palladium on carbon (0.200 g) as a slurry in 
MeOH (8 mL). The flask was evacuated and then purged with H2 
gas three times before leaving to stir under an atmosphere of H2 
overnight at room temperature. On completion the pale brown 
solution was filtered through Celite® and the Celite® washed with 
EtOAc (70 mL). The filtrate was concentrated under reduced 
pressure to yield a crude pale-brown oil which was purified by 
flash column chromatography (90% EtOAc/hexane) to give 22 as 
an orange oil (1.88 g, 6.16 mmol, 96%); Rf 0.26 (90% 
(W2$FKH[DQH,5Ȟmax (neat) 3112 , 2940, 2863, 1630, 1588 cm-
1; 1H NMR (600 MHz, CDCl3į+EUV1H), 7.36 (1 H, 
d, J = 8.6, ArCH), 7.03 (1 H, d, J =2.3, ArCH), 6.81 (1 H, dd, J 
=8.6, 2.3, ArCH), 2.58 (3 H, s, N=CMe), 1.29 ± 1.21 (3 H, m, 
CHMe2), 1.09 (18 H, d, J =7.4, CHMe2); 13C NMR (151 MHz, 
CDCl3 į  C), 151.2 (C), 138.9 (C), 134.0 (ArC), 115.9 
(CH), 114.9 (CH), 104.4 (CH), 18.1 (CH3), 15.0 (CH3), 12.8 (CH); 
m/z (ES+) 305 (100%, [M+H]+); HRMS C17H29N2OSi [M+H]+  
calcd. 305.2049, found 305.2043. 
2-methyl-6-((triisopropylsilyl)oxy)-1-((2- 
(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole (23a) and 
2-methyl-5-((triisopropylsilyl)oxy)-1-((2-
(trimethylsilyl)ethoxy)methyl)-1H- benzo[d]imidazole (23b) 
Solid KH (30% dispersion in mineral oil, 0.738 g, 5.52 mmol) 
was cooled to 0 °C. Compound 22 (1.35 g, 4.45 mmol) was 
dissolved in THF (20 mL) and added drop-wise to the cooled KH 
over a period of 25 mins. Care was taken to ensure that the internal 
temperature of the reaction mixture did not exceed 5 °C. The 
mixture was stirred for 1 h at 0-5 °C before 2-
(trimethylsilyl)ethoxymethyl chloride (0.982 mL, 5.52 mmol) was 
added drop-wise at 0 °C to the thick, sandstone coloured 
suspension. After stirring at room temperature for 19 h, the 
reaction mixture was cooled to 0 °C and water (15 mL) cautiously 
added drop-wise to quench the reaction. The aqueous layer was 
extracted with EtOAc (25 mL x 3). The organic layers were 
combined, dried (MgSO4), filtered and concentrated under reduced 
pressure to yield the crude product as a brown oil. Purification by 
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flash column chromatography (30% EtOAc/petroleum ether) 
gave in order of elution compound 23a as an off-white solid (0.766 
g, 1.76 mmol, 40%), followed by compound 23b as an off-white 
solid (0.795 g, 1.83 mmol, 41%).  
Data for Compound 23a: mp 58 ± 59 °C; Rf 0.28 (40% EtOAc 
SHWUROHXPHWKHU ,5Ȟmax (neat solid) 2947 ± 2867 (C-H), 1622 
(C=N);  1H NMR (600 MHz, CDCl3į+GJ =8.6, ArCH), 
7.18 (1 H, d, J =2.2, ArCH), 6.85 (1 H, dd, J =8.6, 2.2, ArCH), 
5.41 (2 H, s, NCH2O), 3.50 (2 H, t, J =8.4, OCH2CH2Si), 2.62 (3 
H, s, N=CMe), 1.30 ± 1.26 (3 H, m, CHMe2), 1.10 (18 H, d, J =7.5, 
CHMe2), 0.88 (2 H, t, J =8.4, CH2Si), -0.07 (9 H, s, SiMe3); 13C 
NMR (151 MHz, CDCl3įC), 152.4 (C), 143.3 (C), 130.6 
(C), 116.6 (CH), 109.5 (CH), 109.3 (CH), 73.0 (CH2), 66.7 (CH2), 
18.3 (CH3), 14.2 (CH2), 13.0 (CH3), -1.1 (CH3); m/z (ES+) 435 
(100%, [M+H]+), 421 (28%, [M+ -CH3]); HRMS C23H43N2O2Si2 
[M+H]+ calcd. 435.2863, found 435.2858. 
Data for Compound 23b: mp 59 ± 60 °C; Rf 0.15 (40% EtOAc 
SHWUROHXPHWKHU ,5Ȟmax (neat solid) 2945 ± 2867 (C-H), 1621 
(C=N);  1H NMR (600 MHz, CDCl3į+GJ =8.6, ArCH), 
6.87 (1 H, d, J =2.2, ArCH), 6.81 (1 H, dd, J =8.6, 2.2, ArCH), 
5.38 (2 H, s, CH2), 3.50 (2 H, t, J =8.2, OCH2CH2Si), 2.61 (3 H, s, 
N=CMe), 1.29 ± 1.25 (3 H, m, CHMe2), 1.10 (18 H, d, J =7.5, 
CHMe2), 0.88 (2 H, t, J =8.2, CH2Si), -0.06 (9 H, s, SiMe3); 13C 
NMR (151 MHz, CDCl3įC), 151.3 (C), 137.1 (C), 136.1 
(C), 119.3 (CH), 115.8 (CH), 100.2 (CH), 72.8 (CH2), 66.5 (CH2), 
18.1 (CH3), 18.0 (CH2), 14.0 (CH), 12.8 (CH3), -1.4 (CH3); m/z 
(ES+) 435 (25%, [M+H]+); HRMS C23H43N2O2Si2 [M+H]+ calcd. 
435.2863, found 435.2837. 
6-((triisopropylsilyl)oxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-
1H-benzo[d]imidazole-2-carbaldehyde (24a) 
To a suspension of selenium dioxide (0.394 g, 3.55 mmol) in 
1,4-dioxane (10 mL) was added 5.0 M tert-butyl hydroperoxide 
solution in decane (0.850 mL, 8.16 mmol) at room temperature 
and the suspension stirred at 90 °C for 30 mins. A solution of 
compound 23a (0.796 g, 1.83 mmol) in 1,4-dioxane (4 mL) was 
added and the mixture was stirred at 110 °C for 5 h. The mixture 
was allowed to cool to room temperature and concentrated in 
vacuo to get a brown oil, to which sat. NaHCO3 solution (15 mL) 
was added. The aqueous layer was extracted with CH2Cl2 (3 x 20 
mL). The organic layers were combined, dried (MgSO4), filtered 
and concentrated in vacuo to afford the crude compound as a 
brown oil which was purified by flash column chromatography 
(10% Et2O/ petroleum ether) to give 24a as a pale yellow oil 
(0.451 g, 1.23 mmol, 67%); Rf 0.64 (10% EtOAc/petroleum 
HWKHU,5Ȟmax (solution in CHCl3) 2946, 2866, 1693, 1617 cm-1; 
1H NMR (600 MHz, CDCl3į+V&HO), 7.76 (1 H, d, 
J = 8.9, ArCH), 7.04 (1 H, d, J =2.3, ArCH), 7.01 (1 H, dd, J 
=8.9, 2.3, ArCH), 5.97 (2 H, s, NCH2O), 3.54 (2 H, t, J = 8.2, 
OCH2CH2Si), 1.34 ± 1.28 (3 H, m, CHMe2), 1.12 (18 H, d, J 
=7.5, CHMe2), 0.88 (2 H, t, J = 8.2, CH2Si), -0.07 (9 H, s, 
SiMe3); 13C NMR (151 MHz, CDCl3įC), 156.3 (C), 
146.0 (C), 138.0 (C), 137.7 (C), 122.8 (CH), 119.6 (CH), 100.9 
(CH), 73.3 (CH2), 66.3 (CH2), 17.9 (CH3), 17.7 (CH2), 12.6 (CH), 
-1.6 (CH3); m/z (ES+) 449 (65%, [M+H]+) HRMS C23H41N2O3Si2 
[M+H]+ calcd. 449.2656, found 449.2643. 
5-((triisopropylsilyl)oxy)-1-((2-(trimethylsilyl) ethoxy) 
methyl)-1H-benzo[d]imidazole-2-carbaldehyde (24b) 
Procedure as that for aldehyde 24a on a 0.97 mmol scale to 
give 24b as a pale yellow oil (0.420 g, 0.936 mmol, 96%); Rf 
(W2$FSHWUROHXPHWKHU,5Ȟmax (solution in CHCl3) 
2947, 2867, 1693, 1618 cm-1; 1H NMR (600 MHz, CDCl3į
10.07 (1 H, s, CHO), 7.48 (1 H, dd, J =8.9, 0.4, ArCH), 7.36 (1 
H, dd, J =2.3, 0.4, ArCH), 7.13 (1 H, dd, J =8.9, 2.3, ArCH), 6.00 
(2 H, s, NCH2O), 3.55 (2 H, t, J =8.2, OCH2CH2Si), 1.33 ± 1.29 
(3 H, m, CHMe2), 1.12 (18 H, d, J =7.5, CHMe2), 0.88 (3 H, t, J 
=8.2, CH2Si), -0.08 (9 H, s, SiMe3); 13C NMR (151 MHz, CDCl3) 
įC), 153.9 (C), 146.4 (C), 143.8 (C), 131.6 (C), 122.8 
(CH), 112.3 (CH), 110.3 (CH), 73.4 (CH2), 66.6 (CH2), 18.0 
(CH3), 17.9 (CH2Si), 12.7 (CH), -1.4 (CH3); m/z (ES+) 481 
(100%, [M+CH3OH+H]+), 449 (4%, [M+H]+); HRMS 
C23H41N2O3Si2 [M+H]+ calcd. 449.2656, found 449.2652. 
Methyl (E)-(3-(6-((triisopropylsilyl)oxy)-1-((2-
(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-2-yl)prop-2-
enethioyl)serinate (26a) 
A solution of phosphonate 25 (0.313 g, 1.00 mmol) in THF (5 
mL) was cooled to 0 °C and solid KOt-Bu (0.150 g, 1.33 mmol) 
added. The mixture was allowed to warm to room temperature and 
stirred for 1 h. The mixture was cooled to 0 °C and a solution of 
aldehyde 24a (0.301 g, 0.67 mmol) in THF (3 mL) added drop-
wise and the mixture stirred at room temperature for 3 h. The 
mixture was poured into brine (5 mL) and the organic layer diluted 
with EtOAc (10 mL). The aqueous layer was further extracted with 
EtOAc (2 x 10 mL). The organic extracts were combined and 
further washed with brine (10 mL) and then dried (MgSO4), 
filtered and concentrated under reduced pressure to give the crude 
compound as a deep yellow oil which was purified by flash column 
chromatography (gradient elution: 20% EtOAc/ hexane ± 50% 
EtOAc/hexane) to give 26a as a deep yellow oil (0.212 g, 0.35 
mmol, 35%); Rf   (W2$FSHWUROHXP HWKHU ,5 Ȟmax 
(solution in CHCl3) 3245, 2944, 2863, 1739, 1615 cm-1; 1H NMR 
(600 MHz, CDCl3į +GJ =7.5, NH), 7.95 (1 H, d, J 
=14.7, HC=C), 7.61 (1 H, d, J =14.7, C=CH), 7.55 (1 H, d, J =8.6, 
ArCH), 6.93 ± 6.89 (2 H, m, ArCH), 5.54 (2 H, s, NCH2O), 5.48 ± 
5.44 (1 H, m, HN-CH-CO2Me), 4.34 (1 H, dd, J =11.5, 2.7, 
CHaHbOH), 4.22 (1 H, dd, J =11.5, 2.9, CHaHbOH), 3.82 (1 H, br 
s, OH), 3.68 (3 H, s, OMe), 3.53 (2 H, t, J =8.1, OCH2CH2Si), 1.30 
± 1.26 (3 H, m, CHMe2), 1.12 (18 H, d, J =7.4, CHMe2), 0.90 (2 
H, t, J =8.1, CH2Si), -0.07 (9 H, s, SiMe3); 13C NMR (151 MHz, 
CDCl3į&&C), 148.4 (C), 137.2 (C), 
136.4 (CH), 133.3 (CH), 127.2 (CH), 120.0 (C), 118.4 (CH), 100.5 
(CH), 72.5 (CH2), 66.8 (CH2), 61.8 (CH2), 60.5 (CH), 52.8 (CH3), 
18.1 (CH3), 17.9 (CH2), 12.8 (CH), -1.3 (CH3); m/z (ES+) 608 
(100%, [M+H]+); HRMS C29H50N3O5SSi2 [M+H]+ calcd. 
608.3010, found 608.3010. 
Methyl(E)-(3-(5-((triisopropylsilyl)oxy)-1-((2-
(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-2-yl)prop-2-
enethioyl)serinate (26b) 
Procedure as that for thioamide 26a on a 0.96  mmol of 
phosphonate 25 gave 26b as a deep yellow oil (0.206 g, 0.34 
mmol, 53%); Rf   (W2$FSHWUROHXP HWKHU ,5 Ȟmax 
(solution in CHCl3) 3183 (br), 2941, 2626, 1706, 1600 cm-1; 1H 
NMR (600 MHz, CDCl3į+GJ =7.5, NH), 7.96 (1 H, 
d, J =14.7, HC=C), 7.66 (1 H, d, J =14.7, C=CH), 7.32 (1 H, d, J 
=8.8, ArCH), 7.18 (1 H, d, J =2.3, ArCH), 6.97 (1 H, dd, J =8.8, 
2.3, ArCH), 5.60 (2 H, s, NCH2O), 5.45 (1 H, apt. dt, J =7.5, 3.1, 
HN-CH-CO2Me), 4.27 (1 H, dd, J =11.5, 3.0, CHaHbOH), 4.22 (1 
H, dd, J =11.5, 3.2, CHaHbOH), 3.75 (3 H, s, OMe), 3.54 (2 H, t, J 
=8.2, OCH2CH2Si), 1.33 ± 1.28 (3 H, m, CHMe2), 1.13 (18 H, d, J 
=7.5, CHMe2), 0.91 (3 H, t, J =8.2, CH2Si), -0.07 (9 H, s, SiMe3); 
13C NMR (151 MHz, CDCl3įC), 169.9 (C), 153.2 (C), 
148.7 (C), 142.8 (C), 133.7 (CH), 130.1 (C), 126.5 (CH), 118.7 
(CH), 110.2 (CH), 108.2 (CH), 72.1 (CH2), 66.5 (CH2), 61.5 
(CH2), 60.3 (CH), 52.5 (CH3), 17.7 (CH3), 17.4 (CH2), 12.4 (CH), 
-1.8 (CH3); m/z (ES+) 608 (100%, [M+H]+); HRMS 
C29H50N3O5SSi2 [M+H]+ calcd. 608.3010, found 608.3014. 
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Methyl (E)-(3-(6-hydroxy-1-((2-(trimethylsilyl)ethoxy)methyl)-
1H-benzo[d]imidazol-2-yl)prop-2-enethioyl)serinate (27a) 
A solution of 1.0 M solution of TBAF in THF was added to a 
solution of compound 26a (0.055 g, 0.090 mmol) in THF (1.5 mL) 
at 0 °C. The mixture was left to stir at 0 °C for 10 mins and then 
quenched with a saturated solution of NH4Cl (6 mL) at 0 °C, 
allowed to warm to room temperature, extracted with EtOAc (3 x 
15 mL). The organic extracts were combined and washed with a 
saturated solution of NH4Cl (3 x 20 mL), dried (MgSO4), filtered 
and concentrated under reduced pressure to give the crude 
compound as red oil which was purified by flash-column 
chromatography (gradient elution: 90% EtOAc/petroleum ether ± 
neat EtOAc) to give 27a as a yellow oil (0.029 g, 0.064 mmol, 
65%) as a mixture of E and Z isomers that inter-convert in solvent; 
Rf (W2$FKH[DQH,5Ȟmax (solution in CHCl3) 3242, 
2953, 2895, 1739, 1621 cm-1; 1H NMR (600 MHz, CDCl3 į į
13.69 (0.6 H, br s, -NH for Z-isomer), 8.85 (1 H, br s, -NH for E-
isomer), 7.82 (1 H, d, J =14.7, HC=C for E-isomer), 7.52 ± 7.35 
(2.4 H, m), 6.90 ± 6.73 (4 H, m), 6.51 (0.6 H, d, J =13.5, HC=C 
for Z-isomer), 5.42 (2 H, s, NCH2O; 1.6 H, HN-CH-CO2Me), 5.34 
(1.2 H, s, NCH2O), 4.38 (1 H, dd, J =11.7, 3.3, CH2OH), 4.22 (2.2 
H, m, CH2OH), 3.83 (1.8 H, s, OMe for Z-isomer), 3.75 (3 H, s, 
OMe for E-isomer), 3.50 (3.2 H, m, OCH2CH2Si), 2.55 (1 H, br s, 
-OH), 0.88 (5.4 H, m, CH2Si, ArOH, CH2OH, OH), -0.07 (14.4 H, 
overlapping singlets, SiMe3); 13C NMR (151 MHz, CDCl3į
(C), 192.0 (C), 170.6 (C), 170.3 (C), 154.0 (C), 153.7 (C), 148.7 
(C), 147.9 (C), 142.7 (C), 141.7 (C), 137.7 (CH), 133.9 (CH), 
129.7 (CH), 129.1 (CH), 115.7 (CH), 113.7 (CH), 110.9 (CH), 
110.4 (CH), 104.4 (CH), 104.0 (CH), 72.6 (CH2), 72.3 (CH2), 67.0 
(CH2), 66.9 (CH2), 62.2 (CH2), 62.0 (CH2), 53.0 (CH3), 53.0 (CH3), 
18.1 (CH2), 17.8 (CH2), -1.3 (CH3); m/z (ES+) 452 (55%, [M+H]+); 
HRMS C20H30N3O5SSi [M+H]+ calcd. 452.1675, found 452.1686. 
Methyl (E)-(3-(5-hydroxy-1-((2-(trimethylsilyl)ethoxy)methyl)-
1H-benzo[d]imidazol-2-yl)prop-2-enethioyl)serinate (27b) 
Procedure as that for 27a on a 0.069 mmol gave to afford the 
title compound as a yellow oil (0.029 g, 0.064 mmol, 93%); Rf 
  (W2$FKH[DQH ,5 Ȟmax (solution in CHCl3) 3252, 
3037, 2949, 2850, 1737, 1620 cm-1; 1H NMR (600 MHz, CDCl3) 
į H, s, NH), 7.81 (1 H, d, J =14.6, HC=C), 7.50 (1 H, d, J 
= 14.6, C=CH), 7.22 (1 H, d, J = 8.7, ArCH), 7.17 (1 H, s, ArCH), 
6.89 (1 H, d, J = 8.7, ArCH), 5.45 (2 H, s, NCH2O), 5.39 ± 5.36 (1 
H, m, HN-CH-CO2Me), 4.20 ± 4.11 (2 H, m, CH2OH), 3.71 (3 H, 
s, OMe), 3.53 (2 H, t, J = 8.2, OCH2CH2Si), 2.76 (1H, br s, OH), 
0.92 (2 H, t, J = 8.2, CH2Si), -0.06 (9 H, s, SiMe3); 13C NMR (151 
MHz, CDCl3į&&C), 148.8 (C), 142.8 
(C), 141.7 (C), 129.8 (CH), 126.6 (CH), 115.3 (CH), 111.0 (CH), 
104.2 (CH), 72.4 (CH2), 67.0 (CH2), 60.7 (CH2), 53.0 (CH3), 17.8 
(CH2), -1.3 (CH3); m/z (ES+) 452 (65%, [M+H]+); HRMS 
C20H30N3O5SSi [M+H]+ calcd. 452.1675, found 452.1678. 
methyl (E)-2-(2-(6-hydroxy-1-((2-
(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-2-yl)vinyl)-
4,5-dihydrothiazole-4-carboxylate (28a) 
A solution of compound 27a (0.021 g, 0.047 mmol) in CH2Cl2 
(1.0 mL) was cooled to -78 °C and diethylaminosulfur trifluoride 
ȝ/ mmol) added. The mixture was stirred at -78 °C for 
90 mins. The mixture was quenched with a sat. solution of 
NaHCO3 (2 mL) at -78 °C, allowed to warm-up slowly to room 
temperature and extracted with CH2Cl2 (3 x 5 mL). The organic 
extracts were combined, dried (MgSO4), filtered and 
concentrated under reduced pressure to give the crude compound 
as red oil which was purified by flash column chromatography 
(70% EtOAc/ hexane) to give 28a as a deep yellow oil (0.013 g, 
0.030 mmol, 65%); Rf (W2$FKH[DQH,5Ȟmax 
(solution in CHCl3) 3163 (br), 2949, 2923, 1731, 1619 cm-1; 1H 
NMR (600 MHz, CDCl3į+GJ =15.8, HC=C), 7.55 (1 
H, d, J =8.7, ArCH), 7.24 (1 H, d, J =15.8, HC=C), 6.91 (1 H, d, 
J =2.0, ArCH), 6.87 (1 H, dd, J =8.7, 2.0, ArCH), 5.46 (2 H, s, 
NCH2O), 5.26 (1 H, t, J =9.1, CHCO2Me), 3.83 (3 H, s, OMe), 
3.70 ± 3.66 (1 H, m, CH2S), 3.63 ± 3.59 (1 H, m, CH2S), 3.53 (2 
H, t, J =8.1, OCH2), 0.90 (2 H, t, J =8.1, CH2Si), -0.06 (9 H, s, 
SiMe3); 13C NMR (151 MHz, CDCl3) 171.1 (C), 169.3 (C), 153.7 
(C), 148.9 (C), 130.3 (C), 129.7 (C), 129.2 (CH), 126.2 (CH), 
114.9 (CH), 110.4 (CH), 104.7 (CH), 78.4 (CH), 72.6 (CH2), 66.9 
(CH2), 53.1 (CH3), 35.1 (CH2), 17.8 (CH2), -1.3 (CH3); m/z (ES+) 
434 (55%, [M+H]+); HRMS C20H28N3O4SSi [M+H]+ calcd. 
434.1570, found 434.1573. 
Methyl (E)-2-(2-(5-hydroxy-1-((2-
(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-2-yl)vinyl)-
4,5-dihydrothiazole-4-carboxylate (28b) 
Procedure as that for thiazoline 28a on a 0.030 mmol scale to 
give 28b as a yellow oil (0.010 g, 0.22 mmol, 67%); Rf 0.23 
(W2$FSHWUROHXPHWKHU,5Ȟmax (solution in CHCl3) 3279 
(br),  2953, 2854, 1741, 1621 cm-1; 1H NMR (600 MHz, CDCl3) 
į+GJ = 15.8, HC=C), 7.30 ± 7.26 (2 H, m, ArCH, 
C=CH), 7.23 (1 H, d, J =2.2, ArCH), 6.94 (1 H, dd, J = 8.7, 2.2, 
ArCH), 5.54 (2 H, s, NCH2O), 5.26 (1 H, t, J =  9.1, CHCO2Me), 
3.83 (3 H, s, OMe), 3.68 (1 H, dd, J =11.1, 9.0, CH2S), 3.60 (1 H, 
dd, J = 11.0, 9.1, CH2S), 3.54 (2 H, t, J = 8.1, OCH2), 0.92 ± 0.88 
(3 H, m, CH2Si, OH), -0.06 (9 H, s, SiMe3); 13C NMR (151 MHz, 
CDCl3įC), 169.3 (C), 153.5 (C), 149.0 (C), 143.8 (C), 
130.5 (C), 129.2 (C), 126.3 (CH), 114.8 (CH), 110.4 (CH), 104.9 
(CH), 78.5 (CH), 72.5 (CH2), 66.9 (CH2), 53.0 (CH3), 35.1 (CH2), 
17.8 (CH2), -1.3 (CH3); m/z (ES+) 434 (100%, [M+H]+); HRMS 
C20H28N3O4SSi [M+H]+ calcd. 434.1570, found 434.1571. 
Methyl (E)-2-(2-(6-hydroxy-1H-benzo[d]imidazol-2-yl)vinyl)-
4,5-dihydrothiazole-4-carboxylate (29) 
A solution of compound 28a or 28b (13 mg, 0.030 mmol) in 
CH2Cl2 (2 mL) was cooled to 0 °C and 1.0 M tin(IV) chloride 
solution in CH2Cl2 (0.15 mL, 0.15 mmol) was added. The mixture 
was stirred at 0 °C for 3 h, after which an additional volume of 1.0 
M tin(IV) chloride solution in CH2Cl2 (0.15 mL, 0.15 mmol) added 
and left to stir at 0 °C for 1 h. The mixture was quenched at 0 °C 
with a 0.1 M solution of HCl (5 mL). The CH2Cl2 layer was 
separated and the aqueous layer was neutralised to pH=7 with a 
saturated solution of NaHCO3 and extracted with EtOAc (3 x 10 
mL). The organic extracts were combined, dried (MgSO4), filtered 
and concentrated under reduced pressure to give the crude 
compound as a waxy solid which was purified by trituration with 
CHCl3 (3 x 0.5 mL) and the residue dried to give the ester 29 as a 
brown solid (8.6 mg, 0.028 mmol, 95%); mp 175-176 °C; Rf 0.07 
(2% MeOH/ Et2$F,5Ȟmax (solid state) 3297 (br), 2923, 2853, 
1719, 1639 cm-1; 1H NMR (600 MHz, MeOD-d4) į7.63 (1 H, d, 
J  = 9.0, ArCH), 7.59 (1 H, d, J  = 16.5, HC=C), 7.26 (1 H, 
d, J  =  16.5, HC=C), 7.16 (1 H, dd, J  =  9.0, 2.2, ArCH), 7.08 
(1 H, d, J  = 2.2, ArCH), 5.42 (1 H, t, J  = 9.1, CHCO2Me), 
3.83 (3 H, s, OMe), 3.78 (2 H, dd, J  = 12.6, 9.1, CH2S); 13C 
NMR (151 MHz, MeOD-d4į170.5 (C), 168.7 (C), 157.8 (C), 
143.9 (C), 133.9 (CH), 133.1 (C), 125.2 (C), 122.7 (CH), 119.1 
(CH), 115.9 (CH), 98.8 (CH), 79.4 (CH), 53.3 (CH3), 36.1 (CH2); 
m/z (ES+) 304 (2%, [M+H]+); HRMS C14H14N3O3S [M+H]+ calcd. 
304.0756, found 304.0777. 
(E)-2-(2-(6-hydroxy-1H-benzo[d]imidazol-2-yl)vinyl)-4,5-
dihydrothiazole-4-carboxylic acid (13) 
A solution of ester 29 (10.0 mg, 0.0330 mmol) was dissolved 
in phosphate buffer (10 mL, pH=7.8), and treated with PLE 
lyophilised powder (9.2 mg) and incubated at 37 °C for 24 h. 
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Solvent was removed in vacuo and the residue obtained 
suspended in a mixture of 1:1 MeOH/CHCl3. The resultant 
precipitate was isolated by filtration and washed with a mixture of 
1:1 MeOH/CHCl3 (10 mL). The washings were combined and 
concentrated in vacuo to give 13 as a yellow solid (6.0 mg, 0.021 
mmol, 63%); mp 190-19&,5Ȟmax (solid state) 3400 (br), 3123, 
2953, 1737, 1619 cm-1; 1H NMR (600 MHz, THF-d8) į+
d, J =8.8, ArCH), 7.36 (1 H, d, J = 16.1, HC=C), 7.33-7.28 (2 H, 
m, HC=C and ArCH), 6.99 (1 H, dd, J =8.8, 2.4, ArCH, 5.22 (1 H, 
t, J =8.9, CHCO2H), 3.69 (1 H, d, CH2S), 3.63 (1 H, d, CH2S); 13C 
NMR (151 MHz, THF-d8įC), 166.7 (C), 160.1 (C), 148.0 
(C), 136.9 (C), 133.7 (CH), 128.2 (CH), 124.2 (CH), 116.3 (CH), 
106.1 (CH), 78.8 (CH), 34.6 (CH2); m/z (ES+) 242 (100%), 597 
(10%, [2M+Na]+); HRMS [C26H18N6O6S2+Na]+  calcd. 597.0627, 
found 597.0650. 
4.3 Enzyme assays 
To prepare the compounds for assays, D-LH2 K+ salt (Regis 
Tech. IL, USA), DL-BILH2, DL-PBIiLH2 and DL-iLH2 were 
dissolved and made up to 10 mg/mL in TEM buffer (100 mM Tris-
acetate, 2 mM ethylenediaminetetraacetic acid (EDTA) and 10 
mM magnesium sulphate (MgSO4)).DL-BIiLH2 (3.3 mg) was 
dissolved in 50 PL dimethylsulfoxide (DMSO) to aid solubility, 
before making up to 10 mg/mL in TEM buffer. These stocks were 
stored dark protected at -20oC. Subsequently, each compound was 
diluted to 600 PM as a working stock prior to its use. 200 PM 
compounds were assayed with 0.167 PM WT, x2, x5, x11 Flucs or 
click beetle red (CBR) in TEM buffer at pH 7.8. Reactions were 
initiated by the addition of 2 mM saturating ATP to obtain specific 
activities, kinetics and bioluminescence spectra using the 
PhotonIMAGER Optima at 29oC. Each substrate was assayed 
separately in separate plates and the assays were repeated starting 
from the 600 PM working stocks (stored at -20oC) 
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